Background: Differences in isoflavone content of soy protein may explain the absence of a dose-response relation between soy protein intake and blood cholesterol concentrations. Objective: To study specifically the effect of soy-associated isoflavones on cholesterol concentrations in well-controlled trials substituting soy protein with dairy or animal protein.
Introduction
The meta-analysis of Anderson et al (1995) did not detect a dose-response relation between soy protein intake and cholesterol lowering, when changes in cholesterol and lipoproteins were adjusted for changes in the control group. One explanation for the absence of the dose-response relation is that a specific as yet unidentified component or a combination of components in soy is responsible for its cholesterol-lowering action. In 2000, the Nutrition Committee of the American Heart Association concluded that daily consumption of at least 25 g of soy protein with associated phytochemicals intact can improve lipid profiles in hypercholesterolemic subjects (Erdman, 2000) . This means that the cholesterol-lowering effect of soy protein could come from a combination of amino acids or peptides with isoflavones, saponins, or other bioactive components. Several authors suggest that consumption of soy protein devoid of isoflavones or consumption of isolated isoflavones may not lower cholesterol levels, whereas soy protein containing the constitutive isoflavones or perhaps enriched in constitutive isoflavones may have a modest low-density lipoprotein (LDL) cholesterol-lowering effect as compared to animal protein (Lichtenstein, 2001; Vitolins et al, 2001) .
We have analysed the independent effects of changes in soy-associated isoflavones on plasma cholesterol and lipo-protein concentrations in 10 well-controlled studies substituting soy protein for dairy or animal protein.
Methods

Study selection
We screened PubMed for studies on the effect of soy protein and isoflavones on blood cholesterol concentrations. The search criteria were soy OR isoflavones AND cholesterol; publication year ranging from 1 January 1995 to 6 June 2002; human studies; and published in English. We found a total of 148 articles on soy and isoflavone experiments. By means of a title scan, 72 were selected for an abstract evaluation. The abstracts of these citations were examined for compliance with the following inclusion criteria. Within a study, the composition of the experimental diets should differ only in the amount of soy and animal proteins and in the amount of soy-associated isoflavones. The subjects needed to be weight stable throughout the study (average change in weight should be between À2 and +2 kg). The design had to eliminate the effect of nonspecific drifts of the outcome variable with time. This is accomplished by either feeding different groups of volunteers different diets side by side (parallel design) or by feeding each volunteer several diets in random order (crossover or Latin square design). Studies with before-and-after designs or linear designs without a control group were excluded as they do not adjust for nonspecific drifts of the outcome variable with time or do not adjust for differences in baseline diets between treatment groups. The feeding periods had to last at least 2 weeks, in order to attain equilibrium in the concentration of blood cholesterol. Further, studies had to report fasting concentrations of total cholesterol and lipoproteins. Initially, we used two additional criteria. One was that in parallel studies each treatment group needed to have a control or run-in period of at least 2 weeks and the other was that only isolated or textured soy protein should be used. However, there were only five studies (Baum et al, 1998; Crouse et al, 1999; Teixeira et al, 2000; Gardner et al, 2001; Van Horn et al, 2001 ) that fulfilled these very stringent selection criteria and we could not rule out the possibility of publication bias. We therefore dropped these two criteria and refer to the remaining ones as the general criteria.
By means of the general criteria, 40 from the 72 abstracts were selected for a full text scan. Nine of the 40 were included in the analysis (Baum et al, 1998; Crouse et al, 1999; Ashton & Ball, 2000; Teixeira et al, 2000; Vigna et al, 2000; Dent et al, 2001; Gardner et al, 2001; Teede et al, 2001; Van Horn et al, 2001) . We also used data from one study in press at the time we submitted our manuscript (Jenkins et al, 2002) . For selection of studies before 1995, Anderson et al's paper that reviewed data from 38 trials was used (Anderson et al, 1995) . We selected 14 references on 19 trials from Anderson et al's meta-analysis for a full text scan. However, none were included in the present analysis. Most of the older studies were excluded because they did not report the amount of isoflavones present in the soy protein or because the control diet was not the same as the treatment diet with respect to dietary fat, cholesterol, or saturated fat. Others were excluded because the article did not report clearly whether the diets were the same or not.
In total, 10 publications met the general selection criteria for the present study (Table 1) . One additional study also fulfilled the selection criteria; however, we did not include it in the present analyses because the dose of isoflavones and soy protein were more than twice as high as those in the other studies (Meinertz et al, 2002) .
Two trials were carried out in men only (Ashton & Ball, 2000; Teixeira et al, 2000) , three studies included men and women (Crouse et al, 1999; Teede et al, 2001; Jenkins et al, 2002) , and five studies included women only (Baum et al, 1998; Vigna et al, 2000; Dent et al, 2001; Gardner et al, 2001; Van Horn et al, 2001) . The average age of the volunteers ranged from 41 to 63 y, mean body mass index ranged from 24 to 28 kg/m 2 , and mean baseline cholesterol concentration ranged from 5.42 to 6.60 mmol/l. All studies employed freeliving subjects. During the soy treatment period, subjects were provided with isolated soy protein, a soy protein supplement, textured soy protein and/or tofu. During the control treatment period, casein, dry milk, a milk protein supplement, dairy and egg protein or cooked lean meat were given, if necessary in combination with other foods to balance the change in macronutrient intake. The change in soy protein intake ranged from 19 to 60 g/day. The change in isoflavones ranged from 1 to 95 mg/day as compared to the control group or treatment. Isoflavone dose is expressed in aglycone units in six studies (Baum et al, 1998; Crouse et al, 1999; Teixeira et al, 2000; Dent et al, 2001; Gardner et al, 2001; Jenkins et al, 2002) . One study (Teede et al, 2001) reports 'basic compound plus respective glycosides', which we divided by 1.666 to convert them to aglycone units. In three studies, the isoflavone form was not reported (Ashton & Ball, 2000; Vigna et al, 2000; Van Horn et al, 2001) . Isoflavone contents were measured in all studies except that by Ashton and Ball (2000) , who used a literature value. Values for the concentrations of total, LDL and high-density lipoprotein (HDL) cholesterol in serum were divided by 1.029 to convert them to plasma values (Laboratory Methods Committee of the Lipids Research Clinics Program, 1977).
Data available
The 10 studies yielded 21 dietary interventions that compared the effect of soy protein with that of dairy or animal protein. The studies included 959 subjects (336 men and 623 women).
Statistical analysis
We subtracted the mean concentration of plasma cholesterol at the end of the control or baseline diet from that at the end of the high-soy-protein diet to calculate the change in plasma cholesterol. In the eight studies with a parallel design, we then adjusted for drift of variables over time by subtracting the changes in total cholesterol and lipoproteins in the control group from those in the treatment group. Thus, we calculated the absolute change in plasma cholesterol and lipoprotein concentrations (mmol/l), which was the main outcome measure. We further included changes in the ratios of total : HDL and HDL : LDL cholesterol. As most studies did not report changes in the ratios, we used mean concentrations of total HDL and LDL cholesterol at the end of each treatment period to estimate the mean ratios. This procedure caused a marginal underestimation of 4% of the total : HDL ratio and of 7% of the HDL : LDL cholesterol ratio (Weggemans et al, 2001) . This implies that the changes in ratios are marginally smaller than those obtained when the mean change in individual ratios would be used. We did not adjust the ratios and their changes for this minor underestimation.
We also studied the effect of isoflavones on the relative change in total cholesterol and lipoproteins (%), which is the change divided by the concentration during the control or baseline diet.
Correlation and regression analysis
We calculated Pearson's correlation coefficients to study the crude relation between changes in soy-associated isoflavones, soy protein and changes in plasma cholesterol and lipoproteins. Linear regression models (General Linear Models procedure, SAS version 6.12) (Kleinbaum et al, 1988) were used to study the independent effects of isoflavones and soy protein, respectively, on total cholesterol and lipoproteins. In the model, we adjusted also for differences between studies and checked whether there was statistical interaction between changes in isoflavones or soy protein and differences between studies. We also used a model in which we included soy protein and isoflavones and their interaction term as explanatory variables. There was no collinearity problem in this analysis because the correlation between changes in soy protein and soy-associated isoflavones was R ¼ 0.29 (P ¼ 0.21). The effect of baseline cholesterol was also studied. We did not use any nonlinear regression models, because the number of studies in our data set was limited. Although studies were selected on the basis of design and duration of the treatments, there were still differences in quality between the studies. For example, the number of subjects per treatment ranged from 15 to approximately 90. To take this into account, it is usual in meta-analyses to weight each study by the reciprocal of the standard error. However, the standard errors of the changes in cholesterol and lipoprotein concentrations were not reported in some of the studies. We therefore weighted each study by the number of subjects, which is inversely proportional to the squared standard error.
Analysis of residuals was performed to check the appropriateness of each model and to detect publication bias, heterogeneity in funnel plots was explored. To this end, the response of plasma cholesterol and lipoproteins to soyassociated isoflavones was plotted against the sample size by study. In the absence of bias, the plots will resemble a symmetrical funnel, as results of small studies will scatter at the left side of the plot with the spread narrowing among the larger studies on the right side of the plot (Egger et al, 1997) .
Results
When we initially included only the five studies that fulfilled the original, very stringent selection criteria, the funnel plot on LDL cholesterol indicated the possible presence of publication bias. After also including five other studies that fulfilled the general criteria, we did not detect any publication bias with regard to changes in LDL or HDL cholesterol, based on visual inspection of the funnel plots (Figures 1a and  b) . The plots resemble a symmetrical funnel as a result of small studies that tend to scatter at the left side of the plot with the spread narrowing among the larger studies on the right side of the plot.
Three of the 21 treatments increased and 18 treatments decreased LDL cholesterol, whereas 19 of the 21 treatments increased and the other two decreased HDL cholesterol concentrations. Consuming on average 36712 g/day soy (mean7s.d.) in combination with 52730 mg/day isoflavones lowered LDL cholesterol by À0.17 mmol/l (95% confidence interval (CI), À0.25 to À0.09 mmol/l) and the ratio of total : HDL cholesterol by À0.26 (95% CI, À0.36 to À0.16). The treatments increased HDL cholesterol by 0.03 mmol/l (95% CI, 0.01-0.06) and the ratio of HDL : LDL cholesterol by 0.02 (95% CI, 0.01-0.03).
Initially , by only looking at the five studies that fulfilled the very stringent selection criteria, we could find that there was a significant correlation between change in soy-associated isoflavones and change in LDL cholesterol (R ¼ À0.59, P ¼ 0.03). However, this result should be interpreted with caution because it is possible that there is publication bias in these results. In addition, there was no evidence of any doseresponse relation between changes in the intake of soyassociated isoflavones with changes in LDL cholesterol when we included the studies that fulfilled the little less-stringent selection criteria (Figure 2a ) (R ¼ À0.33, P ¼ 0.14).
There was also no significant correlation between changes in soy-associated isoflavone intake and changes in HDL cholesterol (Figure 2b ) (R ¼ À0.07, P ¼ 0.76). Furthermore, neither the ratio of total : HDL cholesterol nor the ratio HDL : LDL cholesterol was significantly related to change in isoflavone intake (R ¼ À0.05, P ¼ 0.83 for total : HDL ratio; R ¼ 0.20, P ¼ 0.38 for HDL : LDL ratio).
Correlations between changes in soy protein and blood cholesterol and lipoprotein concentrations were also not significant. When we excluded the two studies that provided the subjects with textured soy protein and tofu and used egg protein or cooked lean meat as a control (Ashton & Ball, 2000; Jenkins et al, 2002) , results did not basically change (results not shown).
Figure 1
Funnel plot of number of subjects per treatment vs change in (a) plasma LDL cholesterol (mmol/l) and (b) plasma HDL cholesterol (mmol/l) in studies fulfilling the very stringent (m) and the general selection criteria (&). *Indicates a data point that represents two independent observations.
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Regression analyses that included soy-associated isoflavones or soy protein and an indicator that adjusted for differences between studies showed similar results as found in the correlation analyses. There was no interaction between the indicator of differences between studies and isoflavones or soy protein on plasma lipoproteins. When we included changes in soy protein and isoflavones in one regression model, results did not basically change either. There was also no interaction between isoflavones and soy protein on plasma lipoproteins. Results were basically similar when we used relative changes in plasma cholesterol and lipoproteins instead of absolute changes (results not shown).
Discussion
This meta-analysis shows that changes in soy-associated isoflavones or in soy protein amount are not related to decreases in LDL or increases in HDL cholesterol. Therefore, differences in isoflavone content of soy protein do not explain the fact that Anderson et al (1995) did not show a dose-response relation between change in soy protein intake and change in LDL cholesterol concentrations. Nevertheless, like Anderson et al (1995) , we found that replacing dairy and animal proteins with soy protein led to 4% lower LDL cholesterol concentrations. In addition, it significantly increased HDL cholesterol concentrations by 3%, whereas Anderson et al (1995) showed an, albeit not significant, increase of 2.4%. In the present meta-analysis, we did not find any significant effect of baseline cholesterol on cholesterol lowering. This may be because of the small range in baseline cholesterol values in the present meta-analysis.
One possible explanation for the absence of any effect of isoflavones on cholesterol concentrations may be that the expression of the dose of isoflavones was not in aglycone units in some studies. Since the glycosides can add 30-40% to the weight of isoflavone aglycones, this would lead to an overestimation of the isoflavone dose. Three studies (Ashton & Ball, 2000; Vigna et al, 2000; Van Horn et al, 2001) did not specify the form of the isoflavone content. In addition, Ashton and Ball (2000) did not measure the actual isoflavone content of tofu used in their study but used a literature value. When we included only these studies that explicitly report the isoflavone aglycone content in the analyses (Baum et al, 1998; Crouse et al, 1999; Teixeira et al, 2000; Dent et al, 2001; Gardner et al, 2001; Jenkins et al, 2002) , results did not basically change. There was no association between change in isoflavones and change in LDL (R ¼ À0.40, P ¼ 0.13 vs R ¼ À0.33, P ¼ 0.14 including all studies) or HDL cholesterol (R ¼ À0.10, P ¼ 0.70 vs R ¼ À0.07, P ¼ 0.76 including all studies).
Another plausible explanation for the lack of a doseresponse relation between soy-associated isoflavones and blood cholesterol concentrations may be that the expression in total isoflavone dose is not the optimal measure of exposure. It is possible that one of the isoflavones is more effective than the others in lowering LDL cholesterol or increasing HDL cholesterol. If the relative amounts of genistein, daidzein, and glycitein differed between the studies, this would weaken the effects. However, there were no large differences in relative amounts of isoflavones between the four studies that reported these values. Daidzein ranged from 31 to 36%, genistein from 54 to 67%, and glycitein from 0 to 9.4% (Baum et al, 1998; Gardner et al, 2001; Teede et al, 2001; Van Horn et al, 2001) . Owing to the small number of studies, we were not able to study the specific effects of the individual isoflavones.
Alcohol-washing
Consumption of soy protein depleted of isoflavones by alcohol washing may not decrease cholesterol concentrations, due to either the low isoflavone content of the soy protein, or disruption of the protein, the protein-isoflavone complex, or some other component of isolated soy protein that is important for its effect on plasma cholesterol concentrations (Anthony et al, 2002) . Two studies included in the present meta-analysis not only provided isolated soy protein with variable doses of isoflavones obtained by alcohol washing, but also textured soy protein or tofu naturally high or low in isoflavones (Ashton & Ball, 2000; Jenkins et al, 2002) . However, results did not basically change when we excluded the two studies that provided textured soy protein and tofu to the subjects (Ashton & Ball, 2000; Jenkins et al, 2002) . 
Soy-associated vs isolated isoflavones
Our results indicate that isoflavones do not have an independent effect on lowering LDL cholesterol in the presence of soy protein. Previous studies showed that isolated isoflavones, that is, in the absence of soy protein, do not affect lipoprotein concentrations either. Three of the published studies on isolated isoflavones fulfilled our selection criteria, providing three dietary comparisons (Samman et al, 1999; Simons et al, 2000; Dewell et al, 2002) . However, because of this small number we did not include them in the present meta-analysis to estimate the effect of isolated isoflavones. Nevertheless, results from the three studies support the hypothesis that isolated isoflavones do not affect LDL cholesterol concentrations. In one welldesigned crossover study, 80 mg isolated isoflavones from soy decreased LDL cholesterol by À0.08 mmol/l (Simons et al, 2000) , whereas in another trial 86 mg isoflavones from red clover increased LDL cholesterol by 0.07 mmol/l (Samman et al, 1999) and in a third study 150 mg of soy-derived isoflavones decreased total cholesterol concentrations by À0.1 mmol/l (Dewell et al, 2002) .
Mechanism responsible for changes in lipoprotein concentrations
The active compound in soy and the mechanism(s) responsible for the LDL cholesterol-lowering and HDL cholesterolincreasing action of soy are still unknown. One reason for the lack of any dose-response relation between soy-associated isoflavones and LDL cholesterol concentrations may be differences between individuals in the capacity of their intestinal flora to produce equol from daidzein, one of the soy-associated isoflavones. Approximately, one-third of the population are good equol producers Setchell et al, 1984) . Equol is an isoflavonoid that is well absorbed and possesses significant oestrogenic activity having affinity for both oestrogen receptor a and b (Morito et al, 2001) . Meyer et al (2002) showed in a crossover trial that only in the eight equol producers, LDL cholesterol concentrations were significantly decreased upon replacing dairy products by soy-based milk or yoghurt, whereas in the 18 poor-equol producers, there were no significant changes.
Another reason may be that there are several other soy compounds that may affect blood cholesterol concentrations. For example, there may be a direct protein or peptide effect on blood cholesterol concentrations (Sirtori & Lovati, 2001 ). In addition, there are several other components associated with soy protein, such as trypsin inhibitors, phytic acid and saponins (Potter, 1995; Oakenfull, 2001) , however, their effects are not well elucidated yet.
In additon, it may also be that the decrease in LDL cholesterol and the increase in HDL cholesterol are not because of the actives in soy protein, but rather the opposite effect on cholesterol concentrations of actives in dairy and animal proteins. In other words, it is also possible that dairy and animal proteins increase LDL cholesterol and lower HDL cholesterol concentrations.
Soy consumption and risk of coronary heart disease In the present meta-analysis, daily consumption of 36 g of soy protein in combination with 52 mg of soy-associated isoflavones lowered LDL cholesterol by À0.17 mmol/l or, À4% on average. The 4% cholesterol lowering is associated with a 10.8 % risk reduction of coronary heart disease (Law et al, 1994) . However, based on data from short-term, controlled clinical trials, the risk reduction of myocardial infarction or coronary heart disease death may only be 4% (Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults, 2001 ). In addition, it is estimated that coronary heart disease risk is further reduced by 9% if the 3% increase in HDL cholesterol is taken into account (Boden, 2000) . Although the use of soy may exert a smaller risk reduction at the individual level than dietary interventions with plant sterols (Law, 2000) or statin treatment (Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults, 2001) , it is still considerable at a population level.
In conclusion, the present meta-analysis shows that changes in soy-associated isoflavones are not related to changes in LDL or HDL cholesterol.
